High-Throughput Screening of Natural Products for Cancer Therapy

 

 Permissions and Reprints

Abstract

Natural products have been the biggest single source of anticancer drugs and there are continued efforts to explore the chemical diversity provided by nature in order to find new lead compounds. Bioassay test methods have developed into high throughput screening assays using both cell-based and molecular approaches. The various ways to detect effects on cell viability and cell proliferation are summarised and examples are given of developments using three-dimensional cultures and cancer stem cells. Cell-based reporter assays have also been created in order to look more directly for effects on specific physiological pathways. The molecular assays include those directed at microtubules and related proteins and at many different protein kinases.

References

• 1 Newman D J, Cragg G M. Natural products as sources of new drugs over the last 25 years.  J Nat Prod. 2007;  70 461-477
  CrossrefPubMedGoogle Scholar
• 2 Butler M S. Natural products to drugs: natural product-derived compounds in clinical trials.  Nat Prod Rep. 2008;  25 475-516
  CrossrefPubMedGoogle Scholar
• 3 Harvey A L. Natural products in drug discovery.  Drug Discov Today. 2008;  13 894-901
  CrossrefPubMedGoogle Scholar
• 4 Mayr L M, Bojanic D. Novel trends in high-throughput screening.  Curr Opin Pharmacol. 2009;  9 580-588
  CrossrefPubMedGoogle Scholar
• 5 Hergenrother P J. Obtaining and screening compound collections: a user's guide and a call to chemists.  Curr Opin Chem Biol. 2006;  10 213-218
  CrossrefPubMedGoogle Scholar
• 6 Frearson J A, Collie I T. HTS and hit finding in academia – from chemical genomics to drug discovery.  Drug Discov Today. 2009;  14 1150-1158
  CrossrefPubMedGoogle Scholar
• 7 Efferth T, Kahl S, Paulus K, Adams M, Rauh R, Boechzelt H, Hao X, Kaina B, Bauer R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells.  Mol Cancer Ther. 2008;  7 152-161
  CrossrefPubMedGoogle Scholar
• 8 Ma X, Wang Z. Anticancer drug discovery in the future: an evolutionary perspective.  Drug Discov Today. 2009;  14 1136-1142
  CrossrefPubMedGoogle Scholar
• 9 Fenical W, Jensen P R, Palladino M A, Lam K S, Lloyd G K, Potts B C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052).  Bioorg Med Chem. 2009;  17 2175-2180
  CrossrefPubMedGoogle Scholar
• 10 Glaser K B, Mayer A M. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality.  Biochem Pharmacol. 2009;  78 440-448
  CrossrefPubMedGoogle Scholar
• 11 Menna M. Antitumor potential of natural products from Mediterranean ascidians.  Phytother Rev. 2009;  8 461-472
  PubMedGoogle Scholar
• 12 Molinski T F, Dalisay D S, Lievens S L, Saludes J P. Drug development from marine natural products.  Nat Rev Drug Discov. 2009;  8 69-85
  CrossrefPubMedGoogle Scholar
• 13 Bailly C. Ready for a comeback of natural products in oncology.  Biochem Pharmacol. 2009;  77 1447-1457
  CrossrefPubMedGoogle Scholar
• 14 Coseri S. Natural products and their analogues as efficient anticancer drugs.  Mini Rev Med Chem. 2009;  9 560-571
  CrossrefPubMedGoogle Scholar
• 15 Peddibhotla S. 3-Substituted-3-hydroxy-2-oxindole, an emerging new scaffold for drug discovery with potential anti-cancer and other biological activities.  Curr Bioactive Compounds. 2009;  5 20-38
  CrossrefPubMedGoogle Scholar
• 16 Hanahan D, Weinberg R A. The hallmarks of cancer.  Cell. 2000;  100 57-70
  CrossrefPubMedGoogle Scholar
• 17 Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström R C, Perälä M, Kallioniemi O. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.  Clin Cancer Res. 2009;  15 6070-6078
  CrossrefPubMedGoogle Scholar
• 18 Guzmán E A, Johnson J D, Carrier M K, Meyer C I, Pitts T P, Gunasekera S P, Wright A E. Selective cytotoxic activity of the marine-derived batzelline compounds against pancreatic cancer cell lines.  Anticancer Drugs. 2009;  20 149-155
  CrossrefPubMedGoogle Scholar
• 19 Galluzzi L, Aaronson S A, Abrams J, Alnemri E S, Andrews D W, Baehrecke E H, Bazan N G, Blagosklonny M V, Blomgren K, Borner C, Bredesen D E, Brenner C, Castedo M, Cidlowski J A, Ciechanover A, Cohen G M, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht B D, El-Deiry W S, Flavell R A, Fulda S, Garrido C, Golstein P, Gougeon M L, Green D R, Gronemeyer H, Hajnóczky G, Hardwick J M, Hengartner M O, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky D J, Knight R A, Kornbluth S, Kumar S, Levine B, Lipton S A, Lugli E, Madeo F, Malomi W, Marine J C, Martin S J, Medema J P, Mehlen P, Melino G, Moll U M, Morselli E, Nagata S, Nicholson D W, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter M E, Piacentini M, Prehn J H, Puthalakath H, Rabinovich G A, Rizzuto R, Rodrigues C M, Rubinsztein D C, Rudel T, Scorrano L, Simon H U, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden K H, Youle R J, Yuan J, Zhivotovsky B, Kroemer G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.  Cell Death Differ. 2009;  16 1093-1107
  CrossrefPubMedGoogle Scholar
• 20 Shum D, Radu C, Kim E, Cajuste M, Shao Y, Seshan V E, Djaballah H. A high density assay format for the detection of novel cytotoxic agents in large chemical libraries.  J Enzyme Inhib Med Chem. 2008;  23 931-945
  CrossrefPubMedGoogle Scholar
• 21 Hägg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman K G, Shoshan M, Linder S. A novel high-through-put assay for screening of pro-apoptotic drugs.  Invest New Drugs. 2002;  20 253-259
  CrossrefPubMedGoogle Scholar
• 22 Antczak C, Takagi T, Ramirez C N, Radu C, Djaballah H. Live-cell imaging of caspase activation for high-content screening.  J Biomol Screen. 2009;  14 956-969
  CrossrefPubMedGoogle Scholar
• 23 Auld D S, Thorne N, Nguyen D T, Inglese J. A specific mechanism for nonspecific activation in reporter-gene assays.  ACS Chem Biol. 2008;  3 463-470
  CrossrefPubMedGoogle Scholar
• 24 Auld D S, Southall N T, Jadhav A, Johnson R L, Diller D J, Simeonov A, Austin C P, Inglese J. Characterization of chemical libraries for luciferase inhibitory activity.  J Med Chem. 2008;  51 2372-2386
  CrossrefPubMedGoogle Scholar
• 25 Shoichet B K. Screening in a spirit haunted world.  Drug Discov Today. 2006;  11 607-615
  CrossrefPubMedGoogle Scholar
• 26 Riss T L, Moravec R A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays.  Assay Drug Dev Technol. 2004;  2 51-62
  CrossrefPubMedGoogle Scholar
• 27 Niles A L, Moravec R A, Eric Hesselberth P, Scurria M A, Daily W J, Riss T L. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers.  Anal Biochem. 2007;  366 197-206
  CrossrefPubMedGoogle Scholar
• 28 Niles A L, Moravec R A, Riss T L. Multiplex caspase activity and cytotoxicity assays.  Methods Mol Biol. 2008;  414 151-162
  PubMedGoogle Scholar
• 29 Cen H, Mao F, Aronchik I, Fuentes R J, Firestone G L. DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells.  FASEB J. 2008;  22 2243-2252
  CrossrefPubMedGoogle Scholar
• 30 Halliwell B. Oxidative stress in cell culture: an under-appreciated problem?.  FEBS Lett. 2003;  540 3-6
  CrossrefPubMedGoogle Scholar
• 31 Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight L A, Di Nicolantonio F, Cree I A. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.  Anticancer Drugs. 2006;  17 913-919
  CrossrefPubMedGoogle Scholar
• 32 Sims J T, Plattner R. MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.  Cancer Chemother Pharmacol. 2009;  64 629-633
  CrossrefPubMedGoogle Scholar
• 33 Liu W M, Dalgleish A G. MTT assays can underestimate cell numbers.  Cancer Chemother Pharmacol. 2009;  64 861-862
  CrossrefPubMedGoogle Scholar
• 34 Plumb J A, Milroy R, Kaye S B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.  Cancer Res. 1989;  49 4435-4440
  PubMedGoogle Scholar
• 35 Gupta P B, Onder T T, Jiang G, Tao K, Kuperwasser C, Weinberg R A, Lander E S. Identification of selective inhibitors of cancer stem cells by high-throughput screening.  Cell. 2009;  138 645-659
  CrossrefPubMedGoogle Scholar
• 36 Kawasaki B T, Hurt E M, Mistree T, Farrar W L. Targeting cancer stem cells with phytochemicals.  Mol Interv. 2008;  8 174-184
  CrossrefPubMedGoogle Scholar
• 37 Desbordes S C, Placantonakis D G, Ciro A, Socci N D, Lee G, Djaballah H, Studer L. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells.  Cell Stem Cell. 2008;  2 602-612
  CrossrefPubMedGoogle Scholar
• 38 Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells.  Biochem Biophys Res Commun. 2009;  390 743-749
  CrossrefPubMedGoogle Scholar
• 39 Thierbach R, Steinberg P. Automated soft agar assay for the high-throughput screening of anticancer compounds.  Anal Biochem. 2009;  387 318-320
  CrossrefPubMedGoogle Scholar
• 40 Budman D R, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.  Anticancer Drugs. 2002;  13 1011-1016
  CrossrefPubMedGoogle Scholar
• 41 Di Nicolantonio F, Neale M H, Knight L A, Lamont A, Skailes G E, Osborne R J, Allerton R, Kurbacher C M, Cree I A. Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.  Anticancer Drugs. 2002;  13 625-630
  CrossrefPubMedGoogle Scholar
• 42 Larsson D E, Hassan S, Larsson R, Oberg K, Granberg D. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.  Cancer Chemother Pharmacol. 2009;  65 5-12
  CrossrefPubMedGoogle Scholar
• 43 Schimmer A D, Thomas M P, Hurren R, Gronda M, Pellecchia M, Pond G R, Konopleva M, Gurfinkel D, Mawji I A, Brown E, Reed J C. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.  Cancer Res. 2006;  66 2367-2375
  CrossrefPubMedGoogle Scholar
• 44 Booth N L, Sayers T J, Brooks A D, Thomas C L, Jacobsen K, Goncharova E I, McMahon J B, Henrich C J. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.  Cancer Immunol Immunother. 2009;  58 1229-1244
  CrossrefPubMedGoogle Scholar
• 45 Kunz-Schughart L A, Freyer J P, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.  J Biomol Screen. 2004;  9 273-285
  CrossrefPubMedGoogle Scholar
• 46 Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis.  J Biomol Screen. 2006;  11 922-932
  CrossrefPubMedGoogle Scholar
• 47 Friedrich J, Seidel C, Ebner R, Kunz-Schughart L A. Spheroid-based drug screen: considerations and practical approach.  Nat Protoc. 2009;  4 309-324
  CrossrefPubMedGoogle Scholar
• 48 Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids.  J Biomol Screen. 2008;  13 1-8
  PubMedGoogle Scholar
• 49 Hartman O, Zhang C, Adams E L, Farach-Carson M C, Petrelli N J, Chase B D, Rabolt J F. Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications.  Biomacromolecules. 2009;  10 2019-2032
  CrossrefPubMedGoogle Scholar
• 50 Adanja I, Debeir O, Mégalizzi V, Kiss R, Warzée N, Decaestecker C. Automated tracking of unmarked cells migrating in three-dimensional matrices applied to anti-cancer drug screening.  Exp Cell Res. 2010;  316 181-193
  CrossrefPubMedGoogle Scholar
• 51 Glaysher S, Clements C, Harvey A L, Cree I A. High throughput screening of potential anti-cancer agents in primary cell culture using an ATP based luminescence assay. Proceedings AACR 101st Annual meeting. Washington, DC; 2010
  PubMedGoogle Scholar
• 52 Milroy L G, Zinzalla G, Loiseau F, Qian Z, Prencipe G, Pepper C, Fegan C, Ley S V. Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia.  Chem Med Chem. 2008;  3 1922-1935
  CrossrefPubMedGoogle Scholar
• 53 Bialkowska A B, Du Y, Fu H, Yang V W. Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening.  Mol Cancer Ther. 2009;  8 563-570
  CrossrefPubMedGoogle Scholar
• 54 Lin W H, Song J S, Chang T Y, Chang C Y, Fu Y N, Yeh C L, Wu S H, Huang Y W, Fang M Y, Lien T W, Hsieh H P, Chao Y S, Huang S F, Tsai S F, Wang L M, Hsu J T, Chen Y R. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors.  Anal Biochem. 2008;  377 89-94
  CrossrefPubMedGoogle Scholar
• 55 Farkas T, Høyer-Hansen M, Jäättelä M. Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux.  Autophagy. 2009;  5 1018-1025
  CrossrefPubMedGoogle Scholar
• 56 Ausseil F, Samson A, Aussagues Y, Vandenberghe I, Creancier L, Pouny I, Kruczynski A, Massiot G, Bailly C. High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources.  J Biomol Screen. 2007;  12 106-116
  CrossrefPubMedGoogle Scholar
• 57 Vandenberghe I, Créancier L, Vispé S, Annereau J P, Barret J M, Pouny I, Samson A, Aussagues Y, Massiot G, Ausseil F, Bailly C, Kruczynski A. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.  Biochem Pharmacol. 2008;  76 453-462
  CrossrefPubMedGoogle Scholar
• 58 Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors.  Bioorg Med Chem. 2009;  17 2225-2235
  CrossrefPubMedGoogle Scholar
• 59 Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, Workman P, Aherne W. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation.  Mol Cancer Ther. 2007;  6 1112-1122
  CrossrefPubMedGoogle Scholar
• 60 Avila C, Hadden M K, Ma Z, Kornilayev B A, Ye Q Z, Blagg B S. High-throughput screening for Hsp90 ATPase inhibitors.  Bioorg Med Chem Lett. 2006;  16 3005-3008
  CrossrefPubMedGoogle Scholar
• 61 Galam L, Hadden M K, Ma Z, Ye Q Z, Yun B G, Blagg B S, Matts R L. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.  Bioorg Med Chem. 2007;  15 1939-1946
  CrossrefPubMedGoogle Scholar
• 62 Amolins M W, Blagg B S. Natural product inhibitors of Hsp90: potential leads for drug discovery.  Mini Rev Med Chem. 2009;  9 140-152
  CrossrefPubMedGoogle Scholar
• 63 Xia M, Huang R, Sun Y, Semenza G L, Aldred S F, Witt K L, Inglese J, Tice R R, Austin C P. Identification of chemical compounds that induce HIF-1alpha activity.  Toxicol Sci. 2009;  112 153-163
  CrossrefPubMedGoogle Scholar
• 64 Nagle D G, Zhou Y D. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).  Curr Drug Targets. 2006;  7 355-369
  CrossrefPubMedGoogle Scholar
• 65 Nagle D G, Zhou Y D. Marine natural products as inhibitors of hypoxic signalling in tumors.  Phytochem Res. 2009;  8 415-429
  PubMedGoogle Scholar
• 66 Vousden K H, Lane D P. p 53 in health and disease.  Nat Rev Mol Cell Biol. 2007;  8 275-283
  CrossrefPubMedGoogle Scholar
• 67 Ishi K, Sugawara F. A facile method to screen inhibitors of protein-protein interactions including MDM2-p 53 displayed on T7 phage.  Biochem Pharmacol. 2008;  75 1743-1750
  CrossrefPubMedGoogle Scholar
• 68 Sasiela C A, Stewart D H, Kitagaki J, Safiran Y J, Yang Y, Weissman A M, Oberoi P, Davydov I V, Goncharova E, Beutler J A, McMahon J B, O'Keefe B R. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen.  J Biomol Screen. 2008;  13 229-237
  CrossrefPubMedGoogle Scholar
• 69 McCulloch M W, Coombs G S, Banerjee N, Bugni T S, Cannon K M, Harper M K, Veltri C A, Virshup D M, Ireland C M. Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.  Bioorg Med Chem. 2009;  17 2189-2198
  CrossrefPubMedGoogle Scholar
• 70 Goldstein D M, Gray N S, Zarrinkar P P. High-throughput kinase profiling as a platform for drug discovery.  Nat Rev Drug Discov. 2008;  7 391-397
  CrossrefPubMedGoogle Scholar
• 71 Kozielski F, DeBonis S, Skoufias D A. Screening for inhibitors of microtubule-associated motor proteins.  Methods Mol Med. 2007;  137 189-207
  PubMedGoogle Scholar
• 72 Altmann K H, Gertsch J. Anticancer drugs from nature – natural products as a unique source of new microtubule-stabilizing agents.  Nat Prod Rep. 2007;  24 327-357
  CrossrefPubMedGoogle Scholar
• 73 Gallagher Jr B M. Microtubule-stabilizing natural products as promising cancer therapeutics.  Curr Med Chem. 2007;  14 2959-2967
  CrossrefPubMedGoogle Scholar
• 74 Klar U, Hoffmann J, Giurescu M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.  Expert Opin Investig Drugs. 2008;  17 1735-1748
  CrossrefPubMedGoogle Scholar
• 75 Browne B C, O'Brien N, Duffy M J, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer.  Curr Cancer Drug Targets. 2009;  9 419-438
  CrossrefPubMedGoogle Scholar
• 76 Eglen R M, Reisine T. The current status of drug discovery against the human kinome.  Assay Drug Dev Technol. 2009;  7 22-43
  CrossrefPubMedGoogle Scholar
• 77 Hartmann J T, Haap M, Kopp H G, Lipp H P. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects.  Curr Drug Metab. 2009;  10 470-481
  CrossrefPubMedGoogle Scholar
• 78 Ivy S P, Wick J Y, Kaufman B M. An overview of small-molecule inhibitors of VEGFR signaling.  Nat Rev Clin Oncol. 2009;  6 569-579
  CrossrefPubMedGoogle Scholar
• 79 Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.  Anticancer Drugs. 2009;  20 851-855
  CrossrefPubMedGoogle Scholar
• 80 Gautschi O, Heighway J, Mack P C, Purnell P R, Lara Jr P N, Gandara D R. Aurora kinases as anticancer drug targets.  Clin Cancer Res. 2008;  14 1639-1648
  CrossrefPubMedGoogle Scholar
• 81 Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer.  Nat Rev Drug Discov. 2009;  8 547-566
  CrossrefPubMedGoogle Scholar
• 82 Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization.  Expert Opin Drug Discov. 2008;  3 607-621
  CrossrefPubMedGoogle Scholar
• 83 Dufau I, Lazzari A, Samson A, Pouny I, Ausseil F. Optimization of a homogeneous assay for kinase inhibitors in plant extracts.  Assay Drug Dev Technol. 2008;  6 673-682
  CrossrefPubMedGoogle Scholar
• 84 Karaman M W, Herrgard S, Treiber D K, Gallant P, Atteridge C E, Campbell B T, Chan K W, Ciceri P, Davis M I, Edeen P T, Faraoni R, Floyd M, Hunt J P, Lockhart D J, Milanov Z V, Morrison M J, Pallares G, Patel H K, Pritchard S, Wodicka L M, Zarrinkar P P. A quantitative analysis of kinase inhibitor selectivity.  Nat Biotechnol. 2008;  26 127-132
  CrossrefPubMedGoogle Scholar
• 85 Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh J W, Lilly M B. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.  Mol Cancer Ther. 2007;  6 163-172
  CrossrefPubMedGoogle Scholar
• 86 Gaisina I N, Gallier F, Ougolkov A V, Kim K H, Kurome T, Guo S, Holzle D, Luchini D N, Blond S Y, Billadeau D D, Kozikowski A P. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.  J Med Chem. 2009;  52 1853-1863
  CrossrefPubMedGoogle Scholar
• 87 Simard J R, Klüter S, Grütter C, Getlik M, Rabiller M, Rode H B, Rauh D. A new screening assay for allosteric inhibitors of cSrc.  Nat Chem Biol. 2009;  5 394-396
  CrossrefPubMedGoogle Scholar
• 88 Simard J R, Getlik M, Grütter C, Pawar V, Wulfert S, Rabiller M, Rauh D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.  J Am Chem Soc. 2009;  131 13286-13296
  CrossrefPubMedGoogle Scholar
• 89 Hashimoto J, Watanabe T, Seki T, Karasawa S, Izumikawa M, Seki T, Iemura S, Natsume T, Nomura N, Goshima N, Miyawaki A, Takagi M, Shin-Ya K. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format.  J Biomol Screen. 2009;  14 970-979
  CrossrefPubMedGoogle Scholar
• 90 Reindl W, Strebhardt K, Berg T. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.  Anal Biochem. 2008;  383 205-209
  CrossrefPubMedGoogle Scholar
• 91 Reindl W, Gräber M, Strebhardt K, Berg T. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.  Anal Biochem. 2009;  395 189-194
  CrossrefPubMedGoogle Scholar
• 92 Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.  Chem Biol. 2008;  15 459-466
  CrossrefPubMedGoogle Scholar
• 93 Kim L C, Song L, Haura E B. Src kinases as therapeutic targets for cancer.  Nat Rev Clin Oncol. 2009;  6 587-595
  CrossrefPubMedGoogle Scholar
• 94 Sperl B, Seifert M H, Berg T. Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.  Bioorg Med Chem Lett. 2009;  19 3305-3309
  CrossrefPubMedGoogle Scholar
• 95 Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.  Chem Rev. 2009;  109 2894-2902
  CrossrefPubMedGoogle Scholar
• 96 Nitiss J L. Targeting DNA topoisomerase II in cancer chemotherapy.  Nat Rev Cancer. 2009;  9 338-350
  CrossrefPubMedGoogle Scholar
• 97 Bakan A, Lazo J S, Wipf P, Brummond K M, Bahar I. Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.  Curr Med Chem. 2008;  15 2536-2544
  CrossrefPubMedGoogle Scholar
• 98 Johnston P A, Foster C A, Tierno M B, Shun T Y, Shinde S N, Paquette W D, Brummond K M, Wipf P, Lazo J S. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.  Assay Drug Dev Technol. 2009;  7 250-265
  CrossrefPubMedGoogle Scholar
• 99 Hammond E, Li C P, Ferro V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.  Anal Biochem. 2010;  396 112-116
  CrossrefPubMedGoogle Scholar
• 100 Shelton C C, Tian Y, Shum D, Radu C, Djaballah H, Li Y M. A miniaturized 1536-well format gamma-secretase assay.  Assay Drug Dev Technol. 2009;  7 461-470
  CrossrefPubMedGoogle Scholar
• 101 Huang H, Tanaka H, Hammock B D, Morisseau C. Novel and highly sensitive fluorescent assay for leucine aminopeptidases.  Anal Biochem. 2009;  391 11-16
  CrossrefPubMedGoogle Scholar
• 102 Hauser A T, Jung M, Jung M. Assays for histone deacetylases.  Curr Top Med Chem. 2009;  9 227-234
  CrossrefPubMedGoogle Scholar
• 103 Zon L I, Le X. Potential of zebrafish for anticancer screening.  Expert Opin Drug Discov. 2008;  3 1451-1460
  CrossrefPubMedGoogle Scholar
• 104 Crawford A D, Esguerra C V, de Witte P A. Fishing for drugs from nature: zebrafish as a technology platform for natural product discovery.  Planta Med. 2008;  74 624-632
  Article in Thieme ConnectPubMedGoogle Scholar
• 105 Maule J, Richardson J, Clements C, Harvey A, Patton E. A pilot screen for natural inhibitors of cancer-relevant signalling pathways. 5th Eur Zebrafish Genet Dev Meeting, Amsterdam. 2007
  PubMedGoogle Scholar

Alan L. Harvey

Strathclyde Institute of Pharmacy and Biomedical Sciences
University of Strathclyde

27 Taylor Street

Glasgow G4 0NR

United Kingdom

Phone: +44 141 5 53 41 55

Fax: +44 141 5 52 83 76

Email: a.l.harvey@strath.ac.uk